AstraZeneca’s (AZN) Trixeo Aerosphere, already licensed for the treatment of chronic obstructive pulmonary disease in adults, has received a positive opinion from the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, endorsing it for use in the European Union, EU, with a next-generation propellant with near-zero Global Warming Potential. This fixed-dose triple-combination therapy, marketed as Breztri Aerosphere in the US, China and Japan, will now have a low carbon footprint comparable to inhaled medicines that do not require a propellant. Based on the CHMP positive opinion, AstraZeneca will now begin to transition its Trixeo supply to the next-generation propellant in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- IONQ CEO Says ‘The Era of Quantum Supremacy Is Just Around the Corner’
- AstraZeneca’s Tozorakimab: A Promising COPD Treatment Under Study
- AstraZeneca’s New Trial on Liver Fibrosis: A Potential Game-Changer?
- AstraZeneca’s Promising Phase 2 Study on Trastuzumab Deruxtecan for HER2 Tumors
- AstraZeneca’s MAGELLAN Study: A New Horizon in NSCLC Treatment